Médecins Sans Frontières (MSF) and sleeping sickness control. From bush to international health space;Médecins Sans Frontières (MSF) et la lutte contre la maladie du sommeil. De la brousse à l'espace sanitaire international

Bulletin de la Societe de Pathologie Exotique

Volumn 102, Issue 1, 2009, Pages 41-48

  d'Alessandro, E ^a  

^a CNRS UMR 6578   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN TRYPANOSOMIASIS; DEVELOPING COUNTRY; HEALTH SERVICE; HUMAN; INTERNATIONAL COOPERATION; PHYSICIAN; RESEARCH; REVIEW; SOCIAL WELFARE;

CHARITIES; DEVELOPING COUNTRIES; HUMANS; INTERNATIONAL AGENCIES; PHYSICIANS; RESEARCH; TRYPANOSOMIASIS, AFRICAN; VOLUNTARY HEALTH AGENCIES;

EID: 61849110278     PISSN: 00379085     EISSN: None     Source Type: Journal    
DOI: 10.3185/pathexo3290     Document Type: Review

References (34)

1. ANCELLE T, BARRET B, FLACHET L & MOREN A - Two epidemics of arsenical encephalopathy in the treatment of trypanosomiasis. Uganda, 1992-1993. Bull Soc Pathol Exot, 1994, 87, 341-346.
2. BACCHI CJ, NATHAN HC, HUTNER 5H, MAC CANN PP & SJOERDSMA A - Polyamine metabolism: a potential therapeutic target in trypanosomes. Science, 1980, 210, 332-334.
3. BALASEGARAM M, HARRIS S, CHECCHI F, GHORASHIAN S, HAMEL C & KARUNAKARA U - Melarsoprol versus eflornithine for treating late-stage Garnbian trypanosomiasis in the Republic of the Congo. Bull World Health Organ, 2006, 84, 783-791.
4. BRUN R. SCHUMACHER R, SCHMID C, KUNZ C & BURRI C - The phenomenon of treatment failures in human african trypanosomiasis. Trop Med Int Health, 2001, 6, 906-914.
5. CABUT S - Libération, 21 février 2001.
6. CATTAND P - Maladie du sommeil: maladie oubliée, maladie prioritaire. Méd Trop, 2003, 63, 217-218.
7. CHAPPUIS F, UDAYRAJ N, STIETENROTH K, MEUSSEN A & BOVIER PA - Eftornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human african trypanosomiasis. Clin Inf Dis, 2005, 41, 748-751.
8. CHECCHI F, PIOLA P, AYIKORU H, THOMAS F, LEGROS D & PRIOTTO G - Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. Plos Negl Trop Dis, 2007, 1, e64
9. CHIRAC P & TORRELE E - Global framework on essential health R&D. Lancet, 2006. 367, 1560-1561.
10. CORDONNIER MN - Pasteur, microbes et controverses. Pour la Science, 2008, 33.
11. HAMEL A - Genése de la campagne pour I'accés aux medicaments essentiels. Humanitairs, 2001, 3, 118-126.
12. KAGER PA - The return of sleeping sickness in an epidemic form: international action for drugs. Wed Tijdschr Geneeskd, 2002, 146, 2527-2530.
13. LEGROS D, FOURNIER C, GASTELLU-ETCHEGORRY M, MAI- SO F & SZUMILIN E - Échecs thérapeutiqués du mélarsoprol parml des patients traités au stade tardif de trypanosomose humaine africaine á T. b. gambiense en Ouganda. Bull Soc Pathol Exot, 1999, 92, 171-172. [http://www.pathexo.fr/pages/bull-somm/1999-T92/1999-3.html]
14. LEGROS D, EVANS F, MAISO F. ENYARU JC & MBULAM- BERI D - Risk factors for treatment failure after melarso- prol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. 1999, 93, 439-442.
15. MATOVU E, ENYARU JC, LEGROS D. SCHMID C, SEEBECK T & KAMINSKI R - Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop Med Int Health, 2001, 6, 407-411.
16. MC CANN PP, BACCHI CJ, CLARKSON AB, SEED JR. NATHAN HC et al. - Further studies on difluoromethylornithine in African trypanosomes. Med Biol. 1981, 59, 434-440.
17. MILORD F - Efficacy and toxicity of éflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet, 1992, 340, 652-655.
18. MSF - Sleeping Sickness. MSF campaign for access to essential medicines, Fact Sheet, May 2004.
19. OLLIVIER G & LEGROS D - Trypanosomiase humaine africaine: historique de la thérapeutique e.t de ses échecs. Trop Med Int Health, 2001, 6, 855-863.
20. PAQUET C, ANCELLE T, GASTELLU-ETCHEGORRY M, CAS- TILLA J & HARNDT I - Persistence of antibodies to Trypanosoma brucei gambiense after treatment of human trypanosomiasis in Uganda. Lancet, 1992, 340, 250.
21. PAQUET C, CASTILLA J, MBULAMBERI D, BEAULIEU MF, GASTELLU-ETCHEGORRY M & MOREN A - Trypanosomiasis from Trypanosoma brucei gambiense in the center of north-west Uganda, Evaluation of 5 years of control (1987-1991). Bull Soc Pathol Exot, 1995, 88, 38-41.
22. PEPIN J, KHONDE N, MAISO F, DOUA F, JAFFAR S et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomised controlled trial. Bull World Health Organ, 2000, 78, 1284-1295.
23. PRIOTTO G - Éflornithine for first-line treatment of trypano. somiasis: assessment of safety and effectiveness, Ibba, South Sudan. Report 567, Epicentre, Paris, 2003.
24. PRIOTTO G, FOGG C, BALASEGARAM M, ERPHAS O, LOU- GA A et al. - Three drug Combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomised clinical trial in Uganda. Plos Clin Trials, 2006, 1, e39.
25. PRIOTTO G. KASPARIAN S, NGOUARMA D, GHORASHIAN S, ARNOLD U et al. Nifurtimox-éflornithine combination therapy for second-stage Gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis, 2007, 45, 1435-1442.
26. PRIOTTO G, PINOGES L, FURSA IB, BURKE B, NICOLAY N, GRILLET G et al. - Safety and effectiveness of first line éflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ, 2008, 336, 679-680.
27. Rédaction de la Revue Prescrire - Maladie du sommeil : la cosmetologie au secours de la santé publique. La Revue Prescrire, 2006, 26, 135-136.
28. ROLLO IM, WILLIAMSON J & LOURIE EM - Studies on the chemotherapy of melaminyl arsenicals and antimonials in laboratory trypanosome infections. Ann Trop Med Parasitol, 1949, 43, 194-208.
29. Van NIEUWENHOVE S, SCHECTER PJ, DECLERCQ J, BONÉ G, BURKE J et al. - Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial. Trans R Soc Trop Med Hyg, 1985, 79), 692-698.
30. WHO - Control and surveillance of African trypanosomiasis. Report of a WHO expert committee, WHO technical Report Series 881. WHO, Geneva, 1998.
31. WHO - HAT treatment and drug resistance network. Report of the second and third steering Committee Meetings, 29 September 1999, Mombasa, Kenya; 28-30 May 2000, Bruges, Belgium, WHO/CDS/CSR/EDC/2001.13.
32. 1u sommeil. OMS, Communique de presse, 3 mai 2001.
33. WHO - 55' Assemblée Mondiale de la Santé. Campagne panafricaine d'éradication de la mouche tse-tsé et de la trypanosomose. Rapport du Secétariat. Point 13.17 de I'ordre du jour provisoire, A55/22, 30 avril. WHO, Geneva, 2002.
34. WHO - Maladies tropicaies, notamment campagne panafricaine d'éradication de la mouche tsé-tsé et de la trypanosomose. Rapport du Secrétariat, 56 AMS, A56/9, 14 avril. WHO, Geneva, 2003.